Agios Pharmaceuticals AGIO AFS Securities
AFS Securities at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's afs securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's AFS securities?
- Agios Pharmaceuticals (AGIO) reported AFS securities of $308.45M in Q1 2026.
- How has Agios Pharmaceuticals's AFS securities changed year-over-year?
- Agios Pharmaceuticals's AFS securities decreased by 41.9% year-over-year, from $531.25M to $308.45M.
- What is the long-term trend for Agios Pharmaceuticals's AFS securities?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's AFS securities has grown at a 26.0% compound annual growth rate (CAGR), from $97.61M to $310.01M.
- What does AFS securities mean?
- Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.